Commodity Channel Index
|Bid||7.18 x 800|
|Ask||8.72 x 800|
|Day's Range||6.87 - 7.72|
|52 Week Range||3.32 - 27.90|
|Beta (5Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.33|
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement.
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
The Compensation Committee of the Board of Directors approved the grants with an effective date of April 30, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.00 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
M.D. Anderson has halted research and development activity on the Houston pharmaceutical firm's product candidates in response to the COVID-19 pandemic.
Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Startek, Inc. (NASDAQ:SRT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 5:00 PM Eastern ...
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 ...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
HOUSTON, March 05, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it.
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Two publicly traded, clinical-stage pharmaceutical companies in Houston worked to better their financial runways Feb. 6 — one through a share purchase agreement, the other through a reverse stock split. Houston-based Moleculin Biotech Inc. (Nasdaq: MBRX), a clinical-stage pharmaceutical company targeting highly resistant tumors, announced a registered direct offering with institutional investors in a Feb. 6 news release. The agreement allows for Moleculin's investors to purchase an aggregate of up to 7.5 million shares and warrants to purchase 5.625 million shares of common stock at a combined public offering price of 80 cents per share.
The effective time of the reverse stock split will be 5 p.m. ET on February 5, 2020. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on February 6, 2020. As previously disclosed, at a special meeting of stockholders held on January 15, 2020, the Company’s stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company’s certificate of incorporation to effect a reverse stock split and a corresponding reduction in the authorized shares of the Company’s common stock.
Bellicum Pharmaceuticals, Inc. (BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss. The stock option was granted on January 31, 2020 with an exercise price equal to the closing price of the Company’s common stock on such date. One-fourth of the shares subject to the stock option will vest on the one-year anniversary of Mr. Strauss’ start date and the remainder of the shares will vest in a series of 36 successive equal monthly installments thereafter.
NEW YORK, NY / ACCESSWIRE / January 31, 2020 / Levi & Korsinsky announces it has commenced an investigation of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) concerning possible breaches of fiduciary duty. ...
Rick Fair has been the CEO of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) since 2017. First, this article will...
HOUSTON, Jan. 24, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new.
Houston-based Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM), a clinical-stage biopharmaceutical company focused on cellular immunotherapies, is selling a local facility to the University of Texas M.D. Anderson Cancer Center. M.D. Anderson will pay $15 million for the 60,000-square-foot facility at 2130 W. Holcombe Blvd., which includes manufacturing, office and laboratory space, according to a Jan. 21 press release and filing with the U.S. Securities and Exchange Commission. Approximately 35 employees at the facility will transfer to M.D. Anderson.
Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to.
HOUSTON, Jan. 16, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
HOUSTON, Dec. 11, 2019 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that.